Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)

NCT04813107 is registered in ClinicalTrials.gov with Jiangsu Yahong Meditech Co., Ltd aka Asieris as lead sponsor.

NCT NCT04813107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04813107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 28, 2021
Completion date
March 1, 2024
Enrollment
79 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder cancer